Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Centessa Pharmaceuticals plc CNTA
$4.68
+$0.05 (1.08%)
На 18:05, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
441569580.00000000
-
week52high
8.22
-
week52low
2.89
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.00000000
-
EPS
-2.42000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 04:00
Описание компании
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Underweight | Overweight | 12 авг 2022 г. |
| Goldman Sachs | Neutral | Neutral | 11 авг 2022 г. |
| BMO Capital | Outperform | Outperform | 11 авг 2022 г. |
| Morgan Stanley | Overweight | Overweight | 15 июл 2022 г. |
| BMO Capital | Outperform | 17 июн 2022 г. | |
| Morgan Stanley | Underweight | Underweight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Templeman Thomas | A | 90000 | 90000 | 01 февр 2023 г. |
| Templeman Thomas | A | 192347 | 60400 | 01 февр 2023 г. |
| GRAINGER DAVID J | A | 115000 | 115000 | 01 февр 2023 г. |
| GRAINGER DAVID J | A | 981305 | 77200 | 01 февр 2023 г. |
| HUSSAIN IQBAL J | A | 100000 | 100000 | 01 февр 2023 г. |
| HUSSAIN IQBAL J | A | 214659 | 67100 | 01 февр 2023 г. |
| Weinhoff Gregory M | A | 115000 | 115000 | 01 февр 2023 г. |
| Weinhoff Gregory M | A | 300615 | 77200 | 01 февр 2023 г. |
| SAHA SAURABH | A | 315000 | 315000 | 01 февр 2023 г. |
| SAHA SAURABH | A | 917375 | 211400 | 01 февр 2023 г. |
Новостная лента
Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
GlobeNewsWire
06 февр 2023 г. в 08:00
BOSTON and LONDON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the Company will present additional data from the open-label extension (OLE) of AP-0101, a Phase 2a study of SerpinPC, a novel inhibitor of activated protein C (APC) being developed for the treatment of hemophilia, during an oral presentation at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), on February 10, 2023. The Company recently announced positive results from the Phase 2a OLE at the 64th American Society of Hematology (ASH) Annual Meeting.
Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting
GlobeNewsWire
03 ноя 2022 г. в 09:04
New efficacy and safety data from 18-months of continued treatment with subcutaneous doses of SerpinPC in subjects with hemophilia accepted for oral presentation New efficacy and safety data from 18-months of continued treatment with subcutaneous doses of SerpinPC in subjects with hemophilia accepted for oral presentation
Wall Street Analysts Predict a 128% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know
Zacks Investment Research
23 июн 2022 г. в 12:24
The mean of analysts' price targets for Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) points to a 127.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BMO Capital Sees Almost 300% Upside On Centessa Stock
Benzinga
17 июн 2022 г. в 14:37
BMO Capital has initiated coverage on Centessa Pharmaceuticals plc (NASDAQ: CNTA) with a price target of $19 (293% upside), and an Outperform rating. The analyst writes that ZF874 is a differentiated oral therapy as it addresses the root cause of AATD.
Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day
GlobeNewsWire
23 мар 2022 г. в 16:30
BOSTON and LONDON, March 23, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the Guggenheim Genomic Medicines & Rare Disease Day on Thursday, March 31, 2022, at 11:00 am Eastern Time.